Complexo Hospitalario Universitario A Coruña (CHUAC), A Coruña

At the Complexo Hospitalario Universitario A Coruña, the Oncology department contributes to research on severe cardiac inflammation, focusing on innovative treatments for acute myocarditis. The studies aim to compare high‑dose pulse corticosteroid therapy with standard supportive care to improve patient outcomes.

• High‑dose pulse corticosteroid therapy for acute myocarditis
• Assessment of cardiac function recovery after novel anti‑inflammatory regimens
• Safety monitoring of intensive steroid protocols in oncology patients

With four active trials and eight investigators, CHUAC leverages a multidisciplinary approach to advance cardiovascular care alongside cancer treatment.

The centre’s research program addresses critical challenges in end‑stage renal disease and related transplant immunology, as well as immune‑targeted therapies for lymphoma. One key goal is to demonstrate that a reduced immunosuppression regimen can maintain graft survival while lowering infection risk.

• Reduced immunosuppression strategies for older adult kidney transplant recipients
• Rituximab and ibrutinib‑based regimens for generalized mantle‑cell lymphoma
• Evaluation of graft and patient survival under modified immunosuppressive protocols

The site’s collaborative environment supports both transplant and hematologic research, reflecting CHUAC’s commitment to improving immune‑related outcomes.

In the field of neoplasms, CHUAC conducts trials aimed at enhancing therapy tolerance and effectiveness for breast cancer subtypes and lymphomas. Studies explore combination regimens that integrate targeted agents with supportive measures to reduce adverse events while maintaining efficacy.

• Improving sacituzumab govitecan tolerance in metastatic triple‑negative and luminal breast cancer
• Comparative analysis of chemo‑immunotherapy arms for mantle‑cell lymphoma
• Monitoring failure‑free survival across experimental treatment combinations

The oncology team at CHUAC, supported by eight investigators, continues to drive forward innovative cancer research within a European network.